pharma · Metastatic Breast Cancer · Advanced Ovarian Cancer · ALLR
Allarity Therapeutics
Allarity Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Tarpon Springs, USA
- Founded
- 2012
- Employees
- 11
- Programs
- 7
- Drugs
- 4
- Patents
- 1
Allarity Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Allarity Therapeutics.
Allarity Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
2X-121
Allarity Therapeutics
Advanced Ovarian Cancer
1 trial -
APO010
Allarity Therapeutics
Relapsed/Refractory Multiple Myeloma
1 trial -
Irofulven
Allarity Therapeutics
Metastatic Castration-Resistant Prostate Cancer Patients
1 trial -
Ixabepilone Injection
Allarity Therapeutics
Metastatic Breast Cancer
1 trial -
LiPlaCis
Allarity Therapeutics
Phase 1: Advanced or Refractory Solid Tumours
1 trial -
PARP inhibitor 2X-121
Allarity Therapeutics
Metastatic Breast Cancer
1 trial
Frequently asked questions
How many clinical projects does Allarity Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.